Connecting you to content on EBSCOhost

Works by Platt, Heather L.

Results: 6

1

A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6).

Published in:

Clinical Infectious Diseases, 2024, v. 79, n. 6, p. 1366, doi. 10.1093/cid/ciae383

By:

Scott, Paul;
Haranaka, Miwa;
Choi, Jung Hyun;
Stacey, Helen;
Dionne, Marc;
Greenberg, David;
Grijalva, Carlos G;
Orenstein, Walter A;
Fernsler, Doreen;
Gallagher, Nancy;
Zeng, Tiantian;
Li, Jianing;
Platt, Heather L;
Group, for the STRIDE-6 Study

Publication type:

Article

2

Modeling Cost-Effectiveness of Universal Varicella Vaccination With Different Varicella Vaccines in the United Kingdom.

Published in:

Clinical Infectious Diseases, 2021, v. 73, n. 5, p. 935, doi. 10.1093/cid/ciab040

By:

Pawaskar, Manjiri;
Burgess, Colleen;
Pillsbury, Matthew;
Kanibir, M Nabi;
Platt, Heather L

Publication type:

Article

3

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents.

Published in:

Human Vaccines & Immunotherapeutics, 2021, v. 17, n. 11, p. 4183, doi. 10.1080/21645515.2021.1975451

By:

Paradis, Erin M.;
Tikhonov, Oleg;
Cao, Xin;
Kharit, Susanna M.;
Fokin, Aleksandr;
Platt, Heather L.;
Wittke, Frederick;
Jotterand, Veronika

Publication type:

Article

4

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults.

Published in:

Human Vaccines & Immunotherapeutics, 2021, v. 17, n. 11, p. 4177, doi. 10.1080/21645515.2021.1975451

By:

Paradis, Erin M.;
Tikhonov, Oleg;
Cao, Xin;
Kharit, Susanna M.;
Fokin, Aleksandr;
Platt, Heather L.;
Banniettis, Natalie

Publication type:

Article

5

A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II)

Published in:

Human Vaccines & Immunotherapeutics, 2020, v. 16, n. 11, p. 2634, doi. 10.1080/21645515.2020.1743122

By:

Silas, Peter E.;
Zissman, Edward N.;
Gardner, Julie;
Helian, Shanjun;
Lee, Andrew W.;
Platt, Heather L.

Publication type:

Article

6

Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.

Published in:

Journal of Viral Hepatitis, 2019, v. 26, n. 9, p. 1127, doi. 10.1111/jvh.13132

By:

Lawitz, Eric;
Gane, Edward;
Feld, Jordan J.;
Buti, Maria;
Foster, Graham R.;
Rabinovitz, Mordechai;
Burnevich, Eduard;
Katchman, Helena;
Tomasiewicz, Krzysztof;
Lahser, Fred;
Jackson, Beth;
Shaughnessy, Melissa;
Klopfer, Stephanie;
Yeh, Wendy W.;
Robertson, Michael N.;
Hanna, George J.;
Barr, Eliav;
Platt, Heather L.;
Gordon, Stuart C.;
Lawitz, Eric J.

Publication type:

Article